Current Status of Immunotherapy for B-cell Lymphoma
10.3971/j.issn.1000-8578.2022.21.0857
- VernacularTitle:B细胞淋巴瘤的免疫治疗现状
- Author:
Yongliang FU
1
;
Wenting HUANG
Author Information
1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Research Article
- Keywords:
B-cell lymphoma;
Immunotherapy;
PD-1;
PD-L1;
CAR-cell
- From:
Cancer Research on Prevention and Treatment
2022;49(2):159-162
- CountryChina
- Language:Chinese
-
Abstract:
Although the first-line treatment regimens represented by R-CHOP have shown good efficacy in B-cell lymphoma, there are still some patients with recurrence and progression. With the advent of the era of tumor immunotherapy, the immunotherapy of B-cell lymphoma has been rapidly developed, including immune checkpoint inhibitors, CAR-cell, tumor microenvironment regulation, etc. This article reviews the current status of immunotherapy of B-cell lymphoma.
